Description

Paclitaxel Concentrate for Infusions 6 mg/ml. 25 ml. (150 mg.) №1

Ingredients:

Each ml contains 6 mg of Paclitaxel. Other ingredients include ethanol, polyoxy 35 castor oil, and citric acid.

Dosage:

The recommended dosage of Paclitaxel concentrate for infusions is determined by the patient’s body surface area and the specific condition being treated. It is administered intravenously by a healthcare professional.

Indications:

Paclitaxel concentrate for infusions is indicated for the treatment of various cancers including breast cancer, ovarian cancer, and non-small cell lung cancer. It works by interfering with the growth and spread of cancer cells in the body.

Contraindications:

Do not use Paclitaxel concentrate for infusions if you are allergic to paclitaxel or any of the other ingredients. It is not recommended for use during pregnancy or breastfeeding.

Directions:

Administered intravenously over 3 to 24 hours. Dosage may vary based on the type of cancer being treated and the patient’s overall health.

Scientific Evidence:

Studies have shown that Paclitaxel concentrate for infusions is effective in the treatment of various types of cancer. Research published in the Journal of Clinical Oncology demonstrated its efficacy in improving survival rates in patients with advanced ovarian cancer.

Additional Information:

It is important to monitor patients closely for signs of hypersensitivity reactions during treatment with Paclitaxel concentrate for infusions. Common side effects may include hair loss, numbness or tingling in the hands or feet, and muscle pain.

Paclitaxel works by disrupting the normal function of microtubules in the cancer cells, preventing cell division and ultimately leading to cell death. This mechanism of action makes it a valuable treatment option in various cancers.

Clinical trials have shown that Paclitaxel, when used in combination with other chemotherapy agents, can significantly improve treatment outcomes and overall survival rates in cancer patients. Its effectiveness has been well-documented in both early and advanced stages of the disease.